MedTrace Logo

Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)

NCT04389658 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1526

Last updated 2020-10-09

No results posted yet for this study

Summary

In late December 2019, a new coronavirus strain emerged in China causing coronavirus disease 2019 (COVID-19). Since then, COVID-19 has become a global pandemic outbreak being declared a "public health emergency of international concern" by the International Health Regulations Emergency Committee of the WHO on January 30, 2020. Several emergency measures have been implemented in different countries such as lockdown, social distancing and testing. However, due to the lack of tests worldwide the real number of affected and/or immunized people remains largely unknown. In this moment, when reopening phases are being undertaken in the majority of countries, the decision to enact any of these measures rests with the judgement of each health care system. However, every country or individual community circumstances may be unique and require contextual consideration based on the severity and time of the pandemic as well as the number of resources available. The present study aims to retrospectively describe the immune and infective spectrum of illness from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in the general asymptomatic population in three main areas of Spain (Madrid, Barcelona and Valencia) with high impact of COVID-19, right after the lockdown period.

Conditions

Sponsors & Collaborators

  • Igenomix

    lead INDUSTRY

Principal Investigators

  • Xavier Santamaria, MD,PhD · Igenomix

  • Carlos Simon, MD,PhD · Igenomix

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-07
Primary Completion
2020-06-10
Completion
2020-08-25

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389658 on ClinicalTrials.gov